Nasdaq

Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

About Checkpoint TherapeuticsCheckpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization ...
Business Wire

Global Immune Checkpoint Inhibitors Market 2019-2023 | High Target Affinity and Specificity to Boost Demand | Technavio | Business Wire

LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global immune checkpoint inhibitors market to grow at a CAGR of more than 19% during the forecast period, according to their latest market ...
ascopubs.org

Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).

Survival outcomes between surgery with adjuvant therapy compared to neoadjuvant therapy with surgery in stage I pancreatic adenocarcinoma: Results from a large national cancer database. This is an ...
ascopubs.org

TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or ...

A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does not ...